Discovery and development of HIV-protease inhibitors (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Discovery and development of HIV-protease inhibitors" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

8doi.org

2^nd place

2semanticscholar.org

11^th place

8^th place

2web.archive.org

1^st place

2gsk.com

low place

1harvard.edu

18^th place

17^th place

1medscape.com

719^th place

636^th place

1uptodate.com

3,771^st place

2,605^th place

doi.org

Cuccioloni, M; Mozzicafreddo, M; Bonfili, L; Cecarini, V; Eleuteri, A. M.; Angeletti, M (2009). "Natural occurring polyphenols as template for drug design. Focus on serine proteases". Chemical Biology & Drug Design. 74 (1): 1–15. doi:10.1111/j.1747-0285.2009.00836.x. PMID 19519739.
Chen, X; Kempf, D. J.; Li, L; Sham, H. L.; Vasavanonda, S; Wideburg, N. E.; Saldivar, A; Marsh, K. C.; McDonald, E; Norbeck, D. W. (2003). "Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands". Bioorganic & Medicinal Chemistry Letters. 13 (21): 3657–60. doi:10.1016/j.bmcl.2003.08.043. PMID 14552751.
Adachi, M; Ohhara, T; Kurihara, K; Tamada, T; Honjo, E; Okazaki, N; Arai, S; Shoyama, Y; Kimura, K; Matsumura, H; Sugiyama, S; Adachi, H; Takano, K; Mori, Y; Hidaka, K; Kimura, T; Hayashi, Y; Kiso, Y; Kuroki, R (2009). "Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography". Proceedings of the National Academy of Sciences. 106 (12): 4641–6. Bibcode:2009PNAS..106.4641A. doi:10.1073/pnas.0809400106. PMC 2660780. PMID 19273847.
Yanchunas Jr, J; Langley, D. R.; Tao, L; Rose, R. E.; Friborg, J; Colonno, R. J.; Doyle, M. L. (2005). "Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors". Antimicrobial Agents and Chemotherapy. 49 (9): 3825–32. doi:10.1128/AAC.49.9.3825-3832.2005. PMC 1195399. PMID 16127059.
Brower, E. T.; Bacha, U. M.; Kawasaki, Y; Freire, E (2008). "Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use". Chemical Biology & Drug Design. 71 (4): 298–305. doi:10.1111/j.1747-0285.2008.00647.x. PMID 18312292. S2CID 8461472.
Kurup, Alka; Mekapati, Suresh; Garg, Rajni; Hansch, Corwin (2003). "HIV-1 Protease Inhibitors: A Comparative QSAR Analysis". Current Medicinal Chemistry. 10 (17): 1679–88. doi:10.2174/0929867033457070. PMID 12871116.
Shi, Haibin; Liu, Kai; Leong, Wendy W.Y.; Yao, Shao Q. (2009). "Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases". Bioorganic & Medicinal Chemistry Letters. 19 (14): 3945–8. doi:10.1016/j.bmcl.2009.03.041. PMID 19328682.
Turk, Boris (2006). "Targeting proteases: successes, failures and future prospects". Nature Reviews Drug Discovery. 5 (9): 785–99. doi:10.1038/nrd2092. PMID 16955069. S2CID 4156908.

gsk.com

"GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)". Archived from the original on 2008-12-03. Retrieved 2008-06-11. GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385). Retrieved November 4th. 2009.
"GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs". Archived from the original on 2009-08-31. Retrieved 2009-11-05.GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs. Retrieved November 4th. 2009.

harvard.edu

ui.adsabs.harvard.edu

Adachi, M; Ohhara, T; Kurihara, K; Tamada, T; Honjo, E; Okazaki, N; Arai, S; Shoyama, Y; Kimura, K; Matsumura, H; Sugiyama, S; Adachi, H; Takano, K; Mori, Y; Hidaka, K; Kimura, T; Hayashi, Y; Kiso, Y; Kuroki, R (2009). "Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography". Proceedings of the National Academy of Sciences. 106 (12): 4641–6. Bibcode:2009PNAS..106.4641A. doi:10.1073/pnas.0809400106. PMC 2660780. PMID 19273847.

medscape.com

emedicine.medscape.com

HIV Disease at eMedicine

nih.gov

pubmed.ncbi.nlm.nih.gov

Cuccioloni, M; Mozzicafreddo, M; Bonfili, L; Cecarini, V; Eleuteri, A. M.; Angeletti, M (2009). "Natural occurring polyphenols as template for drug design. Focus on serine proteases". Chemical Biology & Drug Design. 74 (1): 1–15. doi:10.1111/j.1747-0285.2009.00836.x. PMID 19519739.
Chen, X; Kempf, D. J.; Li, L; Sham, H. L.; Vasavanonda, S; Wideburg, N. E.; Saldivar, A; Marsh, K. C.; McDonald, E; Norbeck, D. W. (2003). "Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands". Bioorganic & Medicinal Chemistry Letters. 13 (21): 3657–60. doi:10.1016/j.bmcl.2003.08.043. PMID 14552751.
Adachi, M; Ohhara, T; Kurihara, K; Tamada, T; Honjo, E; Okazaki, N; Arai, S; Shoyama, Y; Kimura, K; Matsumura, H; Sugiyama, S; Adachi, H; Takano, K; Mori, Y; Hidaka, K; Kimura, T; Hayashi, Y; Kiso, Y; Kuroki, R (2009). "Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography". Proceedings of the National Academy of Sciences. 106 (12): 4641–6. Bibcode:2009PNAS..106.4641A. doi:10.1073/pnas.0809400106. PMC 2660780. PMID 19273847.
Yanchunas Jr, J; Langley, D. R.; Tao, L; Rose, R. E.; Friborg, J; Colonno, R. J.; Doyle, M. L. (2005). "Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors". Antimicrobial Agents and Chemotherapy. 49 (9): 3825–32. doi:10.1128/AAC.49.9.3825-3832.2005. PMC 1195399. PMID 16127059.
Brower, E. T.; Bacha, U. M.; Kawasaki, Y; Freire, E (2008). "Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use". Chemical Biology & Drug Design. 71 (4): 298–305. doi:10.1111/j.1747-0285.2008.00647.x. PMID 18312292. S2CID 8461472.
Kurup, Alka; Mekapati, Suresh; Garg, Rajni; Hansch, Corwin (2003). "HIV-1 Protease Inhibitors: A Comparative QSAR Analysis". Current Medicinal Chemistry. 10 (17): 1679–88. doi:10.2174/0929867033457070. PMID 12871116.
Shi, Haibin; Liu, Kai; Leong, Wendy W.Y.; Yao, Shao Q. (2009). "Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases". Bioorganic & Medicinal Chemistry Letters. 19 (14): 3945–8. doi:10.1016/j.bmcl.2009.03.041. PMID 19328682.
Turk, Boris (2006). "Targeting proteases: successes, failures and future prospects". Nature Reviews Drug Discovery. 5 (9): 785–99. doi:10.1038/nrd2092. PMID 16955069. S2CID 4156908.

ncbi.nlm.nih.gov

Adachi, M; Ohhara, T; Kurihara, K; Tamada, T; Honjo, E; Okazaki, N; Arai, S; Shoyama, Y; Kimura, K; Matsumura, H; Sugiyama, S; Adachi, H; Takano, K; Mori, Y; Hidaka, K; Kimura, T; Hayashi, Y; Kiso, Y; Kuroki, R (2009). "Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography". Proceedings of the National Academy of Sciences. 106 (12): 4641–6. Bibcode:2009PNAS..106.4641A. doi:10.1073/pnas.0809400106. PMC 2660780. PMID 19273847.
Yanchunas Jr, J; Langley, D. R.; Tao, L; Rose, R. E.; Friborg, J; Colonno, R. J.; Doyle, M. L. (2005). "Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors". Antimicrobial Agents and Chemotherapy. 49 (9): 3825–32. doi:10.1128/AAC.49.9.3825-3832.2005. PMC 1195399. PMID 16127059.

semanticscholar.org

api.semanticscholar.org

Brower, E. T.; Bacha, U. M.; Kawasaki, Y; Freire, E (2008). "Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use". Chemical Biology & Drug Design. 71 (4): 298–305. doi:10.1111/j.1747-0285.2008.00647.x. PMID 18312292. S2CID 8461472.
Turk, Boris (2006). "Targeting proteases: successes, failures and future prospects". Nature Reviews Drug Discovery. 5 (9): 785–99. doi:10.1038/nrd2092. PMID 16955069. S2CID 4156908.

uptodate.com

Graziani, Amy L (June 17, 2014). "HIV protease inhibitors". UpToDate.

web.archive.org

"GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)". Archived from the original on 2008-12-03. Retrieved 2008-06-11. GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385). Retrieved November 4th. 2009.
"GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs". Archived from the original on 2009-08-31. Retrieved 2009-11-05.GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs. Retrieved November 4th. 2009.